Users online: 2645    [ij] [ij] [ij] 
Email id

Asian Journal of Pharmaceutical Research
Year : 2021, Volume : 11, Issue : 1
First page : ( 60) Last page : ( 62)
Print ISSN : 2231-5683. Online ISSN : 2231-5691.
Article DOI : 10.5958/2231-5691.2021.00012.5

Flortaucipir (18F) is a radioactive diagnostic agent indicated for use with positron emission tomography (pet) imaging to image the brain: A review

Mr. Bavaskar Sunil R1,*, Mr. Bhurat Mayur R.2

1HOD. D. Pharm Shri. Prakashchand Jain College of Pharmacy and Research, Palaskhede, Jamner, Maharashtra, (India)

2(I/C Principal) Shri. Prakashchand Jain College of Pharmacy and Research, Palaskhede, Jamner, Maharashtra, (India)

*Corresponding Author E-mail: bavaskarsunilkumar@gmail.com

Online published on 27 April, 2021.


Flortaucipir F-18, also known as 18F-T807 and 18F-AV-1451, is a small indole molecule synthesized with a radioactive fluorine isotope. It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. After crossing the blood-brain barrier, flortaucipir F-18 binds to aggregated tau protein, a hallmark of Alzheimer's disease whose incidence correlates well with disease progression. Although flortaucipir F-18 displays low levels of background binding throughout the brain, it does display off-target binding to monoamine oxidase MAO-A and MAO-B, as well as to regions containing high levels of melanin, neuromelanin, and iron It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain[1,2,3].



Flortaucipir F-18, Alzheimer's disease.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
574,185,815 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.